Ideas

Small molecule-based PD-1 pathway blockade for Human cancer therapy: UBTD1 (Ubiquitin domain containing 1) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 19/December/2016, 9.49 pm
Small molecule-based PD-1 pathway blockade for Human cancer therapy: UBTD1 (Ubiquitin domain containing 1) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 19/December/2016, 9.49 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on…

read more

Natural product-derived therapy for enhancing anti-cancer immunity: Curcumin analog EF24 decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 19/December/2016, 10.27 am
Natural product-derived therapy for enhancing anti-cancer immunity: Curcumin analog EF24 decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 19/December/2016, 10.27 am 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from the Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA shows that “The Hippo Pathway Kinases LATS1/2…

read more

Natural product-derived therapy for overcoming chemoresistance in Human cancers: Honokiol increases the expression of CADM1, decreases BMI1 translocation, increases tumor suppressor INK4a/p16 expression and restores chemosensitivity in drug-resistant Human cancers via down regulation of its target gene, 18/December/2016, 11.01 pm
Natural product-derived therapy for overcoming chemoresistance in Human cancers: Honokiol increases the expression of CADM1, decreases BMI1 translocation, increases tumor suppressor INK4a/p16 expression and restores chemosensitivity in drug-resistant Human cancers via down regulation of its target gene, 18/December/2016, 11.01 pm 150 150 Dr Boomi's Genom-2-Discovery Center

From Research findings to Therapeutic opportunity:  The study presented here suggests that Honokiol, by increasing the expression of its target genes, it may: (i) increase the expression of CADM1; (ii) decrease BMI1 translocation; (iii) increase…

read more

Immune enhancement therapy: Annexin A2 (Anxa2) increases SOX2 expression and promotes innate immunity against bacterial infection via down-regulation of its target gene, 18/December/2016, 10.52 pm
Immune enhancement therapy: Annexin A2 (Anxa2) increases SOX2 expression and promotes innate immunity against bacterial infection via down-regulation of its target gene, 18/December/2016, 10.52 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity…

read more

Molecular therapy for triple-negative breast tumors: SMAD7 increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 18/December/2016, 10.40 pm
Molecular therapy for triple-negative breast tumors: SMAD7 increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 18/December/2016, 10.40 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA shows that “PIM1 kinase inhibition as…

read more

Molecular therapy for Bone disorders: MiR-143 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 18/December/2016, 10.33 pm
Molecular therapy for Bone disorders: MiR-143 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 18/December/2016, 10.33 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis…

read more
Start Typing